# Hadean Ventures

> Hadean Ventures is a VC fund in Oslo backing Biotechnology and Health Care. See 33 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oslo, Norway
- Total investments: 33
- Last investment: Dec 2025
- Lead investor: 45%
- Fund size: $105M
- Last fund: Sep 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/hadean-ventures
- Website: http://hadeanventures.com/

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

## Contacts

5 contacts available for Hadean Ventures. Shizune tracks 5 team members at Hadean Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hadean-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $4.3M–$79M |
| Series B | $4.5M–$75M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 17 | 52% |
| Health Care | 13 | 39% |
| Medical | 6 | 18% |
| Pharmaceutical | 5 | 15% |
| Therapeutics | 3 | 9% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 30% |
| Series B | 5 | 15% |
| Series C | 3 | 9% |
| Funding Round | 3 | 9% |
| Venture - Series Unknown | 3 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 5 | 15% |
| Norway | 4 | 12% |
| Austria | 3 | 9% |
| Germany | 3 | 9% |
| Spain | 1 | 3% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Florian Eckhardt | Senior Investment Director | 0 | https://shizune.co/investors/profile/florian-eckhardt |
| Ingrid Akay | Founder and Managing Partner | 7 | https://shizune.co/investors/profile/ingrid-teigland-akay |
| Ingrid Beyer | Head of Investor Relations | 0 | https://shizune.co/investors/profile/ingrid-beyer |
| Roger Franklin | Partner | 6 | https://shizune.co/investors/profile/roger-franklin-fbab |
| Walter Stockinger | Managing Partner | 5 | https://shizune.co/investors/profile/walter-stockinger |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M | Series B | Sep 17, 2025 |  |
| Gesynta Pharma | Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $4.5M | Series B | Jul 22, 2025 |  |
| Actithera | Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M | Series A | Jul 09, 2025 |  |
| Gesynta Pharma | Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $27.6M | Series B | Jan 20, 2025 |  |
| SciRhom | SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development. | $68.1M | Series A | Jul 09, 2024 |  |
| ARTHEx Biotech | ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $46.5M | Series B | May 03, 2023 |  |
| Complement Therapeutics | Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies. | $78.7M | Series A | Apr 17, 2023 |  |
| Alex Therapeutics | Alex Therapeutics, a digital therapeutics company, is changing the way clinicians provide support for patients to change unwanted habits leading to poor medical outcomes. Our proprietary AI-platform is used as the basis when we develop CE-marked software medical devices (Class I) apps for a variety of therapeutic areas. | $5.1M | Venture - Series Unknown | Mar 03, 2023 |  |

10 of 33 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 5 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 5 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 5 deals together
- [Innovestor](https://shizune.co/investors/profile/innovestor) — VC Fund, 4 deals together
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 4 deals together
- [Bonit Capital](https://shizune.co/investors/profile/bonit-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Investinor](https://shizune.co/investors/profile/investinor) — VC Fund
- [Skyfall Ventures](https://shizune.co/investors/profile/skyfall-ventures) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Sweden](https://shizune.co/investors/medical-vc-funds-sweden)
- [Health Care VC Funds in Sweden](https://shizune.co/investors/health-care-vc-funds-sweden)
- [All VC Funds in Norway](https://shizune.co/investors/vc-funds-norway)
- [All Investors in Norway](https://shizune.co/investors/investors-norway)
- [Biotechnology Investors in Norway](https://shizune.co/investors/biotechnology-investors-norway)
- [Biotechnology VC Funds in Norway](https://shizune.co/investors/biotechnology-vc-funds-norway)

## FAQ

### What does Hadean Ventures invest in?

Hadean Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 33 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Hadean Ventures's check size?

Hadean Ventures typically joins rounds of $4.3M–$79M at Series A and $4.5M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hadean Ventures participates in.

### How do I contact Hadean Ventures?

Public channels for Hadean Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hadean Ventures?

The team at Hadean Ventures includes Florian Eckhardt (Senior Investment Director), Ingrid Akay (Founder and Managing Partner) and Ingrid Beyer (Head of Investor Relations). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co